


Applicants filed this application on February 8, 1991, and they have filed no appeal brief. This application meets the pendency requirements for withdrawal of the finality of outstanding rejections and consideration of this amendment under § 1.129(a). Provision for payment of the fee under 37 C.F.R. 1.17(r) accompanies this paper.

In the Claims

10 Please amend the claims as follows.


51. A compound having the formula:



wherein:

15 B is adenosine, N<sup>6</sup>-benzoyladenine, thymine, guanine, 2,6-diaminopurine or N<sup>2</sup>-isobutyrylguanine; and  
 [R<sup>1</sup> is hydrogen or 4,4'-dimethoxytrityl; and]  
 each R<sup>2</sup> is independently hydrogen, phenyl, alkyl (1-12C) or [HTEA<sup>+</sup>]  
hydrogentriethylammonium ion.

20 53. A compound having the formula:



wherein:

25 B is cytosine, N<sup>4</sup>-benzoylcytosine guanine, 2,6-diaminopurine or N<sup>2</sup>-isobutyrylguanine; and  
 [R<sup>1</sup> is hydrogen or 4,4'-dimethoxytrityl; and]  
 each R<sup>2</sup> is independently hydrogen, phenyl, alkyl (1-12C) or [HTEA<sup>+</sup>]  
hydrogentriethylammonium ion.

Add the following new claims. 1,

- 3<sup>3</sup> 55. The compound of claim 51 wherein R<sup>2</sup> is hydrogen.
- 4<sup>4</sup> 56. The compound of claim 55 wherein B is guanine.
57. The compound of claim 55 wherein B is 2,6-diaminopurine.
- 5<sup>5</sup> 58. The compound of claim 55 wherein B is N<sup>2</sup>-isobutyrylguanine.
- 4<sup>6</sup> 59. The compound of claim 55 wherein B is adenine.
- 1<sup>1</sup> 60. The compound of claim 55 wherein B is N<sup>6</sup>-benzoyladenine.
- 4<sup>4</sup> 61. The compound of claim 55 wherein B is thymine.
62. The compound of claim 53 wherein R<sup>2</sup> is hydrogen.
63. The compound of claim 62 wherein B is guanine.
64. The compound of claim 62 wherein B is 2,6-diaminopurine.
65. The compound of claim 62 wherein B is N<sup>2</sup>-isobutyrylguanine.
66. The compound of claim 62 wherein B is cytosine.
67. The compound of claim 62 wherein B is N<sup>4</sup>-benzoylcytosine.--

30

### Remarks

The new claims add compounds for which Applicants have found biological activity against tested herpesviruses, see attached Declaration. New claims 56-58 and 63-65 recite the same bases that were pending in claims in the parent application when the final Office action issued.

35

38